Company: CYTK
Filing Date: 2025-08-08
Form Type: CORRESP
Source: 0001193125-25-176976
Chunk: 1

Company: CYTOKINETICS INC
Filing Date: 2025-08-08
Form: CORRESP
Chunk 1
---
 of aficamten in a pediatric population with symptomatic oHCM. Additionally, we have FOREST-HCM which is an open label extension study designed to assess the long term safety and tolerability of aficamten in patients with HCM. We continue to develop omecamtiv mecarbil in COMET-HF, a Phase 3 clinical trial of omecamtiv mecarbil in patients with symptomatic HFrEF with severely reduced ejection fraction. * * * * * Please advise us if we can provide any further information or assistance to facilitate your review. Please direct any further comments or questions regarding this response letter to me at (949) 929-5744.

| Sincerely,                                        |
| /s/ SUNG H. LEE                                   |
| Sung H. Lee                                       |
| Executive Vice President, Chief Financial Officer |
| Cytokinetics, Incorporated                        |

| cc: | Robert I. Blum, President and Chief Executive Officer |

John Faurescu, Vice President, Associate General Counsel and Corporate Secretary Holly Laughlin, Vice President, Accounting and Corporate Controller Daniel Coleman, Ernst & Young LLP Chadwick Mills, Cooley LLP